INCY News Alert Incyte Corp (INCY) 71.62 12/17/2014 03:57:42

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Incyte Corp (INCY) 71.62 $INCY

Incyte Shares Up 40.2% Since SmarTrend's Buy Recommendation (INCY)
Comtex SmarTrend(R) - Tue Dec 16, 4:55PM CST
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on October 17th, 2014 at $51.08. In approximately 2 months, Incyte has returned 40.21% as of today's recent price of $71.62.
INCY: 71.62 (-0.52)

Incyte (INCY) Gains on Positive Baricitinib Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 4:20PM CST
Incyte (INCY) and Eli Lilly (LLY) announced encouraging results from the phase III RA-BEACON study on baricitinib.
BIIB: 325.13 (-10.67), INCY: 71.62 (-0.52), ABBV: 65.25 (-0.37), LLY: 69.26 (-0.41)

Biotech Stock Roundup: Cubist to be Acquired by Merck, Bluebird Shoots Up on ASH Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 10, 2:10PM CST
Yet another acquisition agreement was announced even as the biotech sector was busy with showcasing data at ASH.
BLUE: 85.87 (-0.33), BIIB: 325.13 (-10.67), VRTX: 110.86 (-2.02), CBST: 96.73 (+0.42), INCY: 71.62 (-0.52), AMGN: 159.44 (-0.16), ARRY: 4.59 (-0.04)

The Zacks Analyst Blog Highlights: Novartis, Amgen, Incyte and Allergan
PR Newswire - Wed Dec 10, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Novartis (NYSE:NVS-Free Report), Amgen (Nasdaq:AMGN-Free Report), Incyte Corp. (Nasdaq:INCY-Free Report) and Allergan (NYSE:AGN-Free Report).
AGN: 205.75 (-3.26), INCY: 71.62 (-0.52), AMGN: 159.44 (-0.16), NVS: 91.65 (+0.01)

Novartis Reports Encouraging Data on Biosimilar of Neupogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 2:15PM CST
Novartis (NVS) announced that its generic arm, Sandoz, reported encouraging data from a phase III study, PIONEER.
AGN: 205.75 (-3.26), INCY: 71.62 (-0.52), AMGN: 159.44 (-0.16), NVS: 91.65 (+0.01)

Shares of INCY Up 51.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Dec 09, 11:00AM CST
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on October 17th, 2014 at $51.08. In approximately 2 months, Incyte has returned 51.78% as of today's recent price of $77.53.
INCY: 71.62 (-0.52)

Primary endpoint achieved in baricitinib Phase 3
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 10:47AM CST

INCY: 71.62 (-0.52), LLY: 69.26 (-0.41)

Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis
PR Newswire - Tue Dec 09, 6:00AM CST
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment. The study included patients with moderately-to-severely active rheumatoid arthritis (RA) who previously failed one or more tumor necrosis factor (TNF) inhibitors and who were taking stable doses of conventional disease-modifying anti-rheumatic drug (cDMARD) therapy. The companies will share results of several ongoing Phase 3 studies in various disclosures in 2015.
INCY: 71.62 (-0.52), LLY: 69.26 (-0.41)

Hairy Cell Leukemia - Pipeline Review, H2 2014
M2 - Tue Dec 09, 4:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/mrscnl/hairy_cell) has announced the addition of the "Hairy Cell Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hairy Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hairy Cell Leukemia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from this proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by this team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hairy Cell Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hairy Cell Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Plexxikon Inc. - Astellas Pharma Inc. - Incyte Corporation - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Inbiopro Solutions Pvt. Ltd. - Biogenomics Limited For more information visit http://www.researchandmarkets.com/research/mrscnl/hairy_cell
INCY: 71.62 (-0.52), AZN: 69.56 (-0.18), AMGN: 159.44 (-0.16), ONTX: 3.94 (-0.12), GSK: 41.92 (+0.62), STML: 15.28 (-0.21)

CURE Magazine and Incyte Honor MPN Heroes
PRWeb - Fri Dec 05, 1:31PM CST
CURE™ magazine, published by Cure Media Group, hosted the 2nd Annual MPN Heroes recognition reception honoring nine individuals in the field of myeloproliferative neoplasms (MPNs) on December 5th in San Francisco prior to the American Society of Hematology's annual meeting. The celebratory event honored this unique group of individuals who have made a difference by going above and beyond the standard of care, demonstrating leadership within the MPN community, or advancing the science of MPNs. The celebration was made possible with support from Incyte Corporation, CancerCare, Cancer Support Community, Leukemia & Lymphoma Society, MPN Advocacy & Education InternationalMPN Education Foundation, MPN Research Foundation, and MPN Education Foundation, and National Organization for Rare Disorders.
INCY: 71.62 (-0.52)

Incyte's Jakafi Gets FDA Approval for Polycythemia Vera - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 12:00PM CST
Incyte's (INCY) Jakafi gained FDA approval for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.
BIIB: 325.13 (-10.67), INCY: 71.62 (-0.52), LLY: 69.26 (-0.41), NVS: 91.65 (+0.01)

Insider Trading Alert - BRCM, LLY And INCY Traded By Insiders
at The Street - Thu Dec 04, 10:30AM CST
Stocks with insider trader activity include BRCM, LLY and INCY
BRCM: 41.61 (-0.68), INCY: 71.62 (-0.52), LLY: 69.26 (-0.41)

FDA clears Jakafi for PV
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 10:18AM CST

INCY: 71.62 (-0.52)

FDA Approves Jakafi(R) (ruxolitinib) for the Treatment of Patients with Uncontrolled Polycythemia Vera
Business Wire - Thu Dec 04, 9:55AM CST
--PV is a rare blood cancer associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack(1)
INCY: 71.62 (-0.52)

1 Big FDA Decision I'm Watching This Month
Cheryl Swanson, The Motley Fool - Motley Fool - Thu Dec 04, 8:15AM CST
Biotech investing is very risky -- failures outnumber successes. Pundits like to joke that small and mid-sized biotechs should come with a black box label: WARNING: A wrong decision can cost you 90% of your investment. On the other hand, what other...
GILD: 100.46 (-2.70), INCY: 71.62 (-0.52), LLY: 69.26 (-0.41), ABBV: 65.25 (-0.37), ENTA: 41.14 (-1.97), NVS: 91.65 (+0.01)

Biotech Stock Roundup: Avanir to be Acquired by Japanese Firm, Biogen Scores in Alzheimer's Study - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 03, 9:51AM CST
Although it was a relatively uneventful week, mergers and acquisitions show no signs of slowing down in the biotech sector.
BIIB: 325.13 (-10.67), AVNR: 16.91 (-0.04), VRTX: 110.86 (-2.02), INCY: 71.62 (-0.52), ALXN: 177.73 (-5.48), PBYI: 195.44 (+0.11), REGN: 396.13 (-4.88)

Uptrend Call Working As Incyte Stock Rises 45.2% (INCY)
Comtex SmarTrend(R) - Tue Dec 02, 9:32AM CST
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on October 17th, 2014 at $51.08. In approximately 2 months, Incyte has returned 45.20% as of today's recent price of $74.17.
INCY: 71.62 (-0.52)

Multiple Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting Showcase Incyte's Leadership in the Field of Myeloproliferative Neoplasms (MPNs)
Business Wire - Tue Dec 02, 12:15AM CST
--Data from the COMFORT, JUMP, and EXPAND trials reinforce the efficacy and safety of ruxolitinib in patients with myelofibrosis (MF)
INCY: 71.62 (-0.52)

PDUFA date approaches for Jakafi label expansion myelofibrosis
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 12:43PM CST

INCY: 71.62 (-0.52)

2nd Half Of 2014 Biotechnology Catalysts: Part 5
Alexander Maxwell - at Seeking Alpha - Mon Dec 01, 8:59AM CST

BCRX: 10.23 (+0.14), CBST: 96.73 (+0.42), INCY: 71.62 (-0.52), ABBV: 65.25 (-0.37), POZN: 9.03 (+0.10), ENTA: 41.14 (-1.97)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 94

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 209

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 17

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 139

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 94

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 203

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 97

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 167

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 58

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Strategies for Trading Key Stocks: SPY, AAPL & More

Updated Category News Views 72

Morning Trading Insights for Major Stocks Good Morning Traders! In today's Market Clubhouse Morning Memo, we'll take a closer look at key stocks such as SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA. Keeping an eye on these stocks could be crucial for your trading strategy today. Using our proprietary formula exclusive to Market Clubhouse, we determine price levels...

Continue Reading
Precious Metals Shine as Gold Miners Show Strong Growth

Updated Category News Views 194

Gold Miners Surge Ahead of Broader Metals Market The precious metals sector is currently thriving, with gold miners exhibiting significant growth and surpassing previous resistance levels. This encouraging trend is apparent as the GDX index, which tracks the performance of gold mining companies, continues its upward trajectory. Comparison of Junior and Regular Miners...

Continue Reading
MacGregor Revamps Fleet for Wallenius Wilhelmsen Deal

Updated Category News Views 207

MacGregor's Big Move: Retrofitting 35 Vessels I'll tell you something right off the bat—the maritime industry's always got some sea changes brewing, but this latest one’s a real head-turner. MacGregor, those wizards of heavy machinery, have sealed a deal to retrofit 35 ships for Wallenius Wilhelmsen. We’re talking a serious overhaul here, folks, with programmable...

Continue Reading
Nokia Corporation Announces Share Transfer for Incentive Plans

Updated Category News Views 207

Nokia Corporation's Recent Share Transfers Nokia Corporation has recently made significant changes involving its own shares, reflecting its ongoing commitment to its equity-based incentive plans. A total of 5,348 Nokia shares (Helsinki:NOKIA) were transferred today to participants of these plans, emphasizing the company's engagement with its employees and stakeholders....

Continue Reading
Director Peter Hammond Acquires Shares in Adsure Services PLC

Updated Category News Views 271

Director's Share Purchase Signals Confidence In a notable move reflecting confidence in future growth, Adsure Services PLC (LSE:ADS) revealed that director Peter John Hammond has acquired 29 ordinary shares priced at £0.21 each. This acquisition has drawn attention due to its nature as a notification under the UK Market Abuse Regulation guidelines. Details of the...

Continue Reading